Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS

Background : Thromboembolic and bleeding events are serious complications associated with the administration of L‐asparaginase (ASP) during the induction phase in children with acute lymphoblastic leukemia (ALL). Prophylactic supplementation of plasma‐derived coagulation products remains controversial. The purposes of this study were to examine the plasma levels of hemostatic proteins during the induction phase and the efficacy of prophylactic replacement of plasma‐derived products.

[1]  H. Jürgens,et al.  Inhibition of hypercoagulation by antithrombin substitution in E. coli L‐asparaginase‐treated children , 2009, European journal of haematology.

[2]  Y. Ishikawa,et al.  Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study. , 2000, International journal of hematology.

[3]  S. Savage,et al.  Catheter-directed thrombolysis in a child with acute lymphoblastic leukemia and extensive deep vein thrombosis. , 2000, Medical and pediatric oncology.

[4]  C. Niemeyer,et al.  Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia , 1999, Klinische Padiatrie.

[5]  A. Sutor,et al.  Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol , 1999, Klinische Padiatrie.

[6]  R. Junker,et al.  Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. , 1999, Blood.

[7]  P. Monagle,et al.  Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. , 1998, The Journal of pediatrics.

[8]  J. Boos,et al.  Changes in coagulation and fibrinolysis in childhood ALL: a two‐step dose reduction of one E. coli asparaginase preparation , 1996, British Journal of Haematology.

[9]  M. Andrew,et al.  Hemostasis in Childhood Acute Lymphoblastic Leukemia: Coagulopathy Induced by Disease and Treatment , 1995, Seminars in thrombosis and hemostasis.

[10]  M. Eves,et al.  Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L‐asparaginase , 1994, American journal of hematology.

[11]  R. Barr,et al.  Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. , 1994, The American journal of pediatric hematology/oncology.

[12]  F. Mandelli,et al.  Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli-asparaginase. A Gimema study , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[13]  A. Giles,et al.  Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. , 1994, Blood.

[14]  M. Andrew,et al.  Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  F. Mandelli,et al.  Evidence of a Hypercoagulable State in Patients with Acute Lymphoblastic Leukemia Treated with Low Dose of E.coli L-Asparaginase: A GIMEMA Study , 1993, Thrombosis and Haemostasis.

[16]  L. Mottola,et al.  A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. , 1991, Haematologica.

[17]  M. Conese,et al.  Unbalanced Coagulation-Fibrinolysis Potential during L-Asparaginase Therapy in Children with Acute Lymphoblastic Leukaemia , 1990, Thrombosis and Haemostasis.

[18]  M. Rybak,et al.  Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. M. Vazquez,et al.  Thromboembolic complications associated with L‐asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma , 1985, Cancer.

[20]  U. Nowak‐Göttl,et al.  Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. , 1995, Haematologica.

[21]  E. Pogliani,et al.  L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. , 1995, Acta haematologica.

[22]  F. Rodeghiero,et al.  Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. , 1990, Thrombosis research.